Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Frontiers in oncology（2024）
摘要
[This corrects the article DOI: 10.3389/fonc.2023.1223282.].
更多查看译文
关键词
renal cell carcinoma,lenvatinib,pembrolizumab,sunitinib,bone metastases,liver metastases
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要